TaiMed Biologics Inc’s (中裕新藥) sales of its Trogarzo HIV treatment are forecast to boom this year after the European Commission on Thursday last week approved it to be marketed, the company said yesterday.
The company plans to begin marketing the drug in Germany this year, as the nation has friendly regulations on drug pricing, allowing companies to market products before wholesale prices are finalized, TaiMed chief financial officer Jack Chen (陳怡成) said by telephone.
Company partner Montreal-based Theratechnologies Inc has begun making connections with hospitals and patients in Germany, targeting sales of the drug by the end of this year or at the beginning of next year, Chen said.
Theratechnologies — TaiMed’s exclusive marketing and distribution partner in more than 30 markets, including the US, Canada and the EU — is to negotiate prices with regulatory bodies in Europe, he said.
The European price has been estimated at 30 percent lower than US$118,000 for a year of treatment in the US, he said.
Trogarzo is a fourth-line treatment and a drug that is designed for people with multi-drug resistance, TaiMed said.
The number of people in Europe with HIV/AIDS who are multi-drug resistant, which means they require alternative treatments, is estimated to be between 20,000 and 25,000, Chen said.
TaiMed is to pay US$5 million to US-based Genentech Inc as a milestone payment, as Genentech developed and licensed the antibody ibalizumab (TMB-355), a key ingredient of Trogarzo.
TaiMed posted revenue of NT$283 million (US$9.12 million) in the first half of this year and expects its full-year revenue to reach NT$800 million thanks to stable sales of Trogarzo in the US, Chen said, adding that the company started marketing the drug in the US in April last year.
It reported a non-operating loss of NT$43 million in the first half, due to a drop in the value of its stake in Theratechnologies, Chen said.
Gross margin fell to 17 percent for the first six months due to low production yield at contract manufacturer WuXi Biologics Co (無錫生物製藥), which is responsible for the production of Trogarzo, Chen said, adding that the yield improved in the third quarter.
Taiwanese suppliers to Taiwan Semiconductor Manufacturing Co. (TSMC, 台積電) are expected to follow the contract chipmaker’s step to invest in the US, but their relocation may be seven to eight years away, Minister of Economic Affairs J.W. Kuo (郭智輝) said yesterday. When asked by opposition Chinese Nationalist Party (KMT) Legislator Niu Hsu-ting (牛煦庭) in the legislature about growing concerns that TSMC’s huge investments in the US will prompt its suppliers to follow suit, Kuo said based on the chipmaker’s current limited production volume, it is unlikely to lead its supply chain to go there for now. “Unless TSMC completes its planned six
Intel Corp has named Tasha Chuang (莊蓓瑜) to lead Intel Taiwan in a bid to reinforce relations between the company and its Taiwanese partners. The appointment of Chuang as general manager for Intel Taiwan takes effect on Thursday, the firm said in a statement yesterday. Chuang is to lead her team in Taiwan to pursue product development and sales growth in an effort to reinforce the company’s ties with its partners and clients, Intel said. Chuang was previously in charge of managing Intel’s ties with leading Taiwanese PC brand Asustek Computer Inc (華碩), which included helping Asustek strengthen its global businesses, the company
Power supply and electronic components maker Delta Electronics Inc (台達電) yesterday said second-quarter revenue is expected to surpass the first quarter, which rose 30 percent year-on-year to NT$118.92 billion (US$3.71 billion). Revenue this quarter is likely to grow, as US clients have front-loaded orders ahead of US President Donald Trump’s planned tariffs on Taiwanese goods, Delta chairman Ping Cheng (鄭平) said at an earnings conference in Taipei, referring to the 90-day pause in tariff implementation Trump announced on April 9. While situations in the third and fourth quarters remain unclear, “We will not halt our long-term deployments and do not plan to
The New Taiwan dollar and Taiwanese stocks surged on signs that trade tensions between the world’s top two economies might start easing and as US tech earnings boosted the outlook of the nation’s semiconductor exports. The NT dollar strengthened as much as 3.8 percent versus the US dollar to 30.815, the biggest intraday gain since January 2011, closing at NT$31.064. The benchmark TAIEX jumped 2.73 percent to outperform the region’s equity gauges. Outlook for global trade improved after China said it is assessing possible trade talks with the US, providing a boost for the nation’s currency and shares. As the NT dollar
RSS